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Abstract AGR2 is overexpressed in multiple cancers,
particularly those arising from breast and prostate tissues,
and higher levels of AGR2 are associated with earlier
patient death. Although AGR2 is normally resident within
the endoplasmic reticulum, the protein has been found in
the extracellular space in several model systems. However,
it has never been expressly demonstrated that this extra-
cellular form of the protein is secreted and does not just
accumulate in the extracellular space as a result of cell
lysis. We show in this paper that AGR2 protein is secreted
by both human and rat mammary epithelial cells in culture.
Furthermore, this secreted form of AGR2 becomes O-
glycosylated, with no detectable presence of N-glycosyla-
tion. Importantly, this post-translationally modified AGR2
is only detected in the conditioned medium from non-leaky
cells, suggesting that membrane integrity must be main-
tained to allow AGR2 glycosylation. The results suggest a
possible role for O-glycosylation in modulating the extra-
cellular functions of AGR2.
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Introduction
Anterior gradient protein 2 (AGR2) is a member of the
protein disulphide isomerase family of endoplasmic retic-
ulum (ER) chaperones [1], and its major role to date
appears to be in promoting the secretion of several mucin
glycoproteins, including MUC1 [2], MUC2 [3, 4], MUC4
[5], MUC5B and MUC5AC [6, 7]. It also appears to pro-
mote cell differentiation and, as such, is involved in the
development of lung [7], breast [8], liver [9] and gut [10]
tissues.
Expression of AGR2 is induced by physiological stress
[11], ER stress [3, 6, 11–14], and is strongly oestrogen- and
androgen-responsive, particularly in breast and prostate
tissue [15–18]. For this reason, overexpression of AGR2 is
often reported in a number of cancers, particularly in those
arising from the breast, prostate, ovary and pancreas. In
these cancers, higher expression levels of AGR2 generally
correlate with decreased patient survival time [5, 19–24].
The reduced survival time is thought to be caused by an
increase in the rate of metastasis of AGR2-expressing
cancers, as a number of studies have shown an increase in
AGR2 expression in metastatic cells relative to their pri-
mary tumours [16, 25–31] and importantly, AGR2 was able
to induce metastasis of a benign rat mammary cell line
when cells overexpressing AGR2 were injected into syn-
geneic rats [16].
AGR2 is largely tethered to the ER through its C-ter-
minal ER-retention sequence [4, 14, 32–34], but several
studies have reported the presence of AGR2 in the extra-
cellular compartment [35–38], although it has never been
demonstrated that this AGR2 is not just simply released as
a result of cell death and lysis. However, in vivo, AGR2
has been detected in both human colonic mucus [35] and
murine intestinal mucus [35–37]. This suggests that AGR2
may have an extracellular role, perhaps in a similar way to
nAG, the newt homologue of AGR2, which binds to the
cell surface receptor Prod1 and can induce limb regenera-
tion in a salamander model [39, 40]. As further evidence of
an extracellular role for AGR2, a recent study showed that
the addition of extracellular recombinant AGR2 to
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pancreatic cancer cells promoted their growth, migration
and invasion by signalling through the C4.4a cell surface
receptor [41]. Interestingly, C4.4a is a structural homo-
logue of the urokinase-type plasminogen activator receptor
(uPAR), which, along with CD59, is the most closely
related human homologue of Prod1 [42]. Extracellularly-
added recombinant AGR2 has also been shown to promote
adhesion of rat mammary epithelial cells [16, 43] and the
migration and tube formation of human umbilical vein
endothelial cells (HUVEC) [38], indicating a possible role
for extracellular AGR2 in the promotion of angiogenesis.
Changes in both cell adhesion and induction of angiogen-
esis may be important for a pro-metastatic phenotype.
The prevalence of AGR2 overexpression in several
tumour types and its correlation with patient survival has
engendered much interest in the use of AGR2 as a serum or
urine biomarker for disease detection [29, 44–47]. Further
understanding of the nature of secreted AGR2 may be
important in maximising the accuracy and sensitivity of
such tests, and may also shed light on the extracellular
functions of AGR2. We show here that AGR2 is O-gly-
cosylated upon secretion from human and rat cell lines, and
that this form of the protein is released from healthy cells
and not as a result of cell lysis.
Materials and methods
Cell culture and transfection
The oestrogen receptor-positive MCF7A human mammary
epithelial cell line was grown in Dulbecco’s Modified
Eagle’s Medium (DMEM, Life Technologies) including
non-essential amino acids (NEAA) and supplemented with
10 % (v/v) foetal bovine serum (FBS), 4 mM L-glutamine
and 10 lg/mL insulin (Sigma). Rama 37 rat mammary
benign epithelial tumour cells [48] were grown in DMEM
including NEAA and supplemented with 5 % (v/v) FBS,
4 mM L-glutamine, 10 ng/mL insulin and 10 ng/mL
hydrocortisone (Sigma). Cells were transfected with the
PiggyBac EF1a-IRES-neomycin plasmid vector (Systems
Biosciences, vector only), or the same vector containing a
human AGR2 cDNA, using FuGENE6 transfection reagent,
according to the manufacturer’s protocol (Promega).
Transfected cellsweremaintained in normal growthmedium
supplemented with 1 mg/mL G418 (Melford). Clonal cell
lines were created by serial dilution of transfected cells down
to a single cell in a known volume and growing these for
several weeks until confluent cultures were obtained.
Collection of conditioned medium
Cells were grown to 30–40 % confluence, washed four
times in phosphate-buffered saline (PBS) supplemented
with 900 lM CaCl2 and 500 lM MgCl2, in order to
remove the maximum amount of FBS whilst limiting cell
detachment. These cells were then incubated in Opti-MEM
(Minimum Essential Medium) serum-free medium (Life
Technologies) supplemented with a final concentration of
25 mM glucose, 1.8 mM CaCl2, 4 % (v/v) non-essential
amino acids (NEAA, Life Technologies) and 10 ng/mL
hydrocortisone, in order to make this serum-free medium
as close to the formulation of normal culture medium as
possible. After 24 h, medium was collected, centrifuged at
10009g at 4 C and concentrated using an Amicon ultra
centrifugal filter (Millipore).
Western blotting
Whole cell lysates were prepared from cells grown to
70–80 % confluence and lysed in RIPA buffer [50 mM
Tris–HCl, pH 6.8, 150 mM NaCl, 2 mM EDTA, 1 % (v/v)
NP-40, 0.5 % (w/v) sodium deoxycholate, 0.1 % (w/v)
SDS and complete protease inhibitor cocktail (Roche)].
Secreted protein samples were obtained as described
above. Samples were subjected to SDS-PAGE, transferred
to PVDF membrane (Millipore) and probed with a mouse
monoclonal antibody specific for AGR2 (Millipore,
MABC48) or a polyclonal rabbit anti-LDHA (Cell Sig-
naling Technology, #2012) serum. Horseradish peroxidase-
coupled secondary antibodies were obtained from Dako.
Protein molecular weights were estimated by plotting a
standard curve of molecular weight and relative migration
distance for known protein standards, and calculating the
molecular weights of different forms of AGR2 using their
relative migration distance.
Enzymatic deglycosylation of proteins
All enzymes and reagents were acquired from New Eng-
land Biolabs. Cell lysates and samples of conditioned
medium were first denatured by incubation with 0.5 % (w/v)
SDS, 40 mM DTT and subsequent heating at 98 C for
5 min. Samples were then subjected to treatment with
either PNGase F, O-glycosidase/neuraminidase mix or
protein deglycosylation mix (consisting of PNGase F, O-
glycosidase, neuraminidase, b1-4 galactosidase and b-N-
acetylglucosaminidase) for 4 h at 37 C, as per the man-
ufacturer’s instructions.
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Results
AGR2 is secreted in a higher molecular weight form
from cultured rat and human mammary cells
A number of studies have reported that AGR2 is secreted,
both from cultured cells [17, 25, 49] and into intestinal
mucus in mice [35]. In the present experiments, AGR2 was
recovered from the culture medium of Rama 37 cells
expressing wild-type (WT) AGR2 protein and displayed an
apparent molecular weight 0.90 (SD ± 0.12) kDa higher
than that of intracellular AGR2 (Fig. 1). This mass dif-
ference in extracellular AGR2 shows that its presence in
the culture medium is not due to intracellular AGR2
released from lysed or leaky cells, and this is further
confirmed by the lack of detectable levels in the culture
medium of AGR2-expressing Rama 37 cells of the intra-
cellular marker protein, lactate dehydrogenase A (LDHA).
To ensure that this release of higher molecular weight
AGR2 was not restricted to transfected rat mammary cells,
the release of AGR2 from AGR2-expressing human
MCF7A cells [16] was investigated (Fig. 2). Furthermore,
to investigate further whether this higher molecular weight
form is actively released from cells rather than released by
cell lysis, MCF7A cells were incubated in increasingly
nutrient-poor media, and the presence of AGR2 in these
conditioned media was monitored by Western blot (Fig. 2).
All incubation media were serum-free (see ‘‘Materials
and methods’’ section), and cells incubated in either
DMEM with or without non-essential amino acids
(NEAA), or with Opti-MEM medium without NEAA
released large amounts of lower molecular weight AGR2
into the culture medium, but there was no detectable higher
molecular weight AGR2 under any of these conditions.
Furthermore, cells incubated in these media also released
high amounts of LDHA, suggesting that AGR2 is released
from these cells as a result of cell lysis. Conversely, cells
incubated in Opti-MEM medium containing NEAA
released a form of AGR2 with apparent molecular weight
0.93 (SD ± 0.09) kDa larger than intracellular AGR2, but
barely detectable levels of LDHA. These data suggest that
the higher molecular weight form of AGR2 is released only
from intact cells that do not leak intracellular proteins.
Secreted AGR2 contains O-linked, but not N-linked,
glycans
Given that only small amounts of AGR2 protein are
secreted from both Rama 37 and MCF7A cells, we created
a Rama 37 cell line expressing a mutant form of AGR2
lacking the C-terminal ER-retention sequence (DKTEL
AGR2), leading to increased secretion of AGR2, and thus
facilitating the determination of the increase in molecular
weight of secreted AGR2. As expected, AGR2 was secre-
ted in higher amounts from DKTEL AGR2-expressing cells
but, interestingly, secreted DKTEL AGR2 displayed the
same sized shift in apparent molecular weight compared to
intracellular WT AGR2 (0.94 (SD ± 0.09) kDa, Fig. 3) as
did secreted WT AGR2 (Fig. 1), despite the KTEL deletion
rendering the intracellular protein apparently 0.87
Fig. 1 A higher molecular weight form of AGR2 is released into the
medium of AGR2-expressing rat mammary epithelial tumour cells.
Conditioned medium was collected from vector only-expressing or
WT AGR2-expressing Rama 37 cells and analysed for the presence of
AGR2 and lactate dehydrogenase (LDHA) by Western blot. The
presence of LDHA in the conditioned medium was used as an
indication of the contamination of the secreted protein pool by
intracellular proteins [64]. Extracellular AGR2 was 0.90 (SD ± 0.12)
kDa larger than intracellular AGR2 on average (n = 3)
Fig. 2 In human mammary epithelial cells, higher molecular weight
AGR2 is only released from non-leaky cells. MCF7A cells were
incubated for 24 h in serum-free DMEM or serum-free Opti-MEM
medium, with and without non-essential amino acids (NEAA).
Conditioned medium was collected and probed for AGR2 and LDHA
by Western blot. The presence of LDHA in the conditioned medium
was used as an indication of the contamination of the secreted protein
pool by intracellular proteins under each serum-free condition.
Extracellular AGR2 was 0.93 (SD ± 0.09) kDa larger than intracel-
lular AGR2 on average (n = 3)
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(SD ± 0.01) kDa smaller than intracellular WT AGR2
(measured by polyacrylamide gel electrophoresis, data not
shown).
As the majority of secreted proteins are glycosylated
[50], it is likely that the cause of the increase in apparent
molecular weight of secreted AGR2 was one or more
glycosylation events. Indeed, secreted DKTEL AGR2 (but
not intracellular WT AGR2) reacted weakly with periodic
acid-Schiff stain, a glycoprotein stain (data not shown).
Therefore, we investigated the nature of the probable gly-
cosylation using specific deglycosylating enzymes (Fig. 4).
Conditioned medium from DKTEL AGR2-expressing
cells treated with the N-glycosidase PNGase F showed no
change in the apparent molecular weight of AGR2,
remaining 0.80 (SD ± 0.04) kDa larger than intracellular
AGR2, both with and without PNGase F treatment
(Fig. 4a). Under these same reaction conditions, however,
PNGase F reduced the apparent molecular weight of a-acid
glycoprotein by approximately 30 kDa, indicating that the
enzyme was active in the conditioned medium (Fig. 4b).
Treatment of DKTEL AGR2-conditioned medium with
either O-glycosidase (and neuraminidase) or a commercial
mix of deglycosylation enzymes, consisting of PNGase F,
O-glycosidase, neuraminidase, b1-4 galactosidase and b-N-
acetylglucosaminidase, reduced the apparent molecular
weight of secreted AGR2 by 0.53 (SD ± 0.04) kDa, but
not back down to the apparent molecular weight of intra-
cellular AGR2. Deglycosylation enzymes had no effect on
the size of intracellular AGR2 (Fig. 4a). These experiments
indicate that the secreted form of AGR2 does not contain
any detectable N-glycosylation sites, but contains at least
one digestible O-glycosylation site.
Discussion
It is shown here for the first time that AGR2 secreted from
both rat and human mammary epithelial cells becomes O-
glycosylated. While it was possible to distinguish that
secreted AGR2 was O-glycosylated, but not N-glycosy-
lated, it is clear that neither treatment with O-glycosidase/
neuraminidase nor the deglycosylation enzyme cocktail
(Fig. 4) fully reduced the apparent molecular weight of the
secreted AGR2 to that of the unmodified intracellular
AGR2. This likely reflects the presence of glycan structures
not digestible by the enzymes used herein, but while
secreted AGR2 is not phosphorylated (data not shown), we
cannot totally rule out the presence of some other, less
common, post-translational modification. In addition, the
similar-sized shift in apparent molecular weight observed
between secreted WT and DKTEL AGR2 (Figs. 1, 3),
despite the smaller size of the DKTEL polypeptide chain,
implies that the secreted DKTEL AGR2 may be more
heavily glycosylated than WT protein. The presence of a
KTEL sequence has been previously shown to alter the
make-up of O-linked glycans, and probably relates to the
differences in transit time of the protein from ER to Golgi
and to the extracellular space [51]. Due to the limitations of
the SDS polyacrylamide gel electrophoresis technique, it
was not possible to draw further conclusions about the
detailed nature of the O-linked modifications from size
differences of the observed bands.
Possible sites of these O-glycosylated residue(s) in
AGR2 are shown in Fig. 5, based on prediction by the
NetOGlyc 4.0 server [52]. All of these predicted sites lie
within the unstructured N-terminal region of AGR2, which
we described previously [43], consistent with a recent
bioinformatics finding that O-glycosylation sites are loca-
ted preferentially in unstructured protein regions, whereas
the opposite is true for N-glycosylation [53].
AGR2 is an ER-resident chaperone protein and other
such chaperones have also been reported to be secreted
[54–57]. Notably, the AGR2-related protein disulphide
isomerase, ERp44, which, like AGR2, contains a divergent
CXXS-active site, is O-glycosylated upon secretion [57]. It
is possible therefore that O-glycosylation of normally ER-
resident chaperones by the Golgi body is a more general
phenomenon, rather than an AGR2-specific event, and may
stem from ‘leakiness’ of the KDEL-dependent retrograde
transport of proteins from Golgi to ER [51]. Furthermore,
although most secreted proteins passing through the Golgi
are glycosylated, there are several examples of non-gly-
cosylated secreted proteins, notably insulin [58], serum
albumin [59] and elastin [60]. This suggests that glycosy-
lation of secreted ER proteins may have functional con-
sequences, rather than being the result of some default
Fig. 3 A highly secreted mutant form of AGR2 is also released in a
high molecular weight form from rat mammary tumour cells. Rama
37 cells were engineered to express AGR2 devoid of the C-terminal
KTEL ER-retention sequence in order to increase its secretion. Note
that, as DKTEL AGR2 is highly secreted, intracellular levels are
almost undetectable and thus expression of intracellular WT AGR2 is
shown for size comparison. Extracellular AGR2 was 0.94
(SD ± 0.09) kDa larger than intracellular AGR2 on average (n = 3)
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programme of glycosylation for any protein passing
through the Golgi.
It is not yet known how the presence of the O-linked
glycosylation might affect the biological activity of AGR2.
The protein plays a role in cell adhesion [16, 43], although it
should be noted that these experiments were performed
using bacterially-derived (i.e. non-glycosylated) AGR2, but
it is interesting that O-glycosylation status has been reported
to influence cell adhesion; for example, in pancreatic
carcinoma cells, enhancement or reduction of cell adhesion
depended upon the cell surface O-linked glycosylation state
of the cells [61], and similarly, alterations in the O-glyco-
sylation patterns of the transmembrane proteins a2b1 inte-
grin and E-cadherin altered the migratory and invasive
potential of pancreatic adenocarcinoma cells [62]. Loss of
O-glycosylation sites in the secreted metastasis-inducing
protein osteopontin was also shown to increase its pro-ad-
hesive effects [63]. Thus, the degree and pattern of O-
Fig. 4 Treatment with O-glycosidase reduces the molecular weight
of secreted AGR2. a Conditioned medium from DKTEL AGR2-
expressing cells (secreted AGR2) and whole cell lysate from WT
AGR2-expressing cells (intracellular AGR2) were treated with the
indicated deglycosylation enzymes for 4 h at 37 C, as per the
manufacturer’s instructions. Treated samples were subjected to
Western blot and probed for AGR2. PNGase F is an N-glycosidase.
O-glycosidase-treated samples were simultaneously treated with
neuraminidase, as the presence of terminal sialic acid residues blocks
the activity of O-glycosidase [65]. Deglycosylation mix consists of
PNGase F, O-glycosidase, neuraminidase, b1-4 galactosidase and b-
N-acetylglucosaminidase. Untreated extracellular AGR2 was 0.80
(SD ± 0.04) kDa larger than intracellular AGR2 on average (n = 3),
and extracellular AGR2 treated with O-glycosidase or deglycosyla-
tion mix was 0.27 (SD ± 0.04) kDa larger than intracellular AGR2 on
average (n = 3). b To ensure that PNGase F was active in the
presence of culture medium components, a-acid glycoprotein (a-AG)
was added to conditioned medium and treated with PNGase as in a.
Reaction mixtures were run on an SDS-PAGE gel and stained with
Coomassie blue
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glycosylation in both cell surface and secreted proteins
appear to play roles in cell adhesion. We have already
shown that the unstructured region of AGR2, comprising
amino acids 21–40, is required for AGR2-promoted cell
adhesion [43], and we have shown here that it is also the
possible site of O-linked glycosylation in AGR2 (Fig. 5).
Glycosylation of extracellular AGR2 may therefore be
important for AGR2-mediated cell adhesion.
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